Prodia Seeks New Growth Engine, Targets Regenerative Therapy Amid Weak Purchasing Power
PT Prodia Widyahusada Tbk. (PRDA) is beginning to shift its business direction by entering regenerative therapy services, amid pressure from weak societal purchasing power and limitations in laboratory business growth. This step marks the healthcare services issuer’s effort to find new growth sources beyond its mainstay diagnostic services.
Prodia Chief Executive Dewi Muliaty stated that service development is being carried out to meet societal needs, particularly related to increasingly prevalent degenerative diseases.
“Prodia continues to commit to delivering health service innovations focused on societal needs, including the development of regenerative treatment therapy based on stem cells,” she said in her official statement quoted on Monday (20/4/2026).
Prodia’s entry into this segment is strengthened through the acquisition of 30% shares in PT Prodia StemCell Indonesia (ProSTEM) worth Rp33 billion in 2025, as a foundation for developing biotechnology-based therapy.
However, unlike the relatively massive expansion of laboratory services, the development of regenerative therapy is being carried out more cautiously. Prodia acknowledges that the market for these services is not yet broad and still heavily depends on societal absorption capacity.
“Every time we open something new, there must be market absorption. We can’t just open directly,” said Dewi.
On the other hand, the cost structure also poses a challenge. Dewi emphasised that the largest investment is actually in medical personnel, not facilities.
“The most expensive investment is doctors. Their expertise is what is expensive,” she said.
This condition makes services like stem cell therapy tend to be in the premium segment, thus not yet fully accessible to the wider public. Meanwhile, the need for preventive and regenerative health services continues to increase, in line with the growing elderly population and changes in disease patterns.
Prodia itself has only recently started these services at the Prodia Senior Health Centre, targeting degenerative diseases such as osteoarthritis and osteoporosis.
Looking ahead, the company plans to expand similar services to other major cities, while still considering market absorption and the availability of medical personnel.
This step is also part of Prodia’s business development in the regenerative therapy and advanced therapy medicinal products (ATMP) sector in Indonesia.